REFERENCES
- Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analy-sis. Arch Intern Med. 2005;165:2337–44.
- Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Investigators of the Club Rhumatismes et Inflammation. Lymphomas in rheumatoid arthritis patients treated with metho-trexate: a 3-year prospective study in France. Blood. 2002;99: 3909–15.
- Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996;14:1943–9.
- Dawson TM, Starkebaum G, Wood BL, Willkens RF, Gown AM. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjogren's syndrome: case series. J Rheumatol. 2001;28:47–53.
- Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med. 1993;119:1093–104.
- Batara JF, Grossman SA. Primary central nervous system lym-phomas. Curr Opin Neurol. 2003;16:671–5.
- O'Neill BP, Vernino S, Dogan A, Giannini C. EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro Oncol. 2007;9:364–9.
- Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094–108.
- Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to metho-trexate medication. J Rheumatol. 2007;34:322–31.
- Hsu JL, Glaser SL. Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol. 2000;34:27–53.
- Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. Blood Rev. 2008;22: 261–81.
- Kleinschmidt-DeMasters BK, Damek DM, Lillehei KO, Dogan A, Giannini C. Epstein Barr virus-associated primary CNS lym-phomas in elderly patients on immunosuppressive medications. J Neuropathol Exp Neurol. 2008;67:1103–11.
- Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.